Jane J. Zara

Array ( [id] => 13586629 [patent_doc_number] => 20180344863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => TDNs-AS1411-Nucleic Acid Drug Nanocomposite Based Drug Delivery System and Preparation Method Thereof [patent_app_type] => utility [patent_app_number] => 15/555380 [patent_app_country] => US [patent_app_date] => 2016-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15555380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383805 [patent_doc_number] => 20180243444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => NOVEL PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE-STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE [patent_app_type] => utility [patent_app_number] => 15/753328 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522555 [patent_doc_number] => 20180312820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta [patent_app_type] => utility [patent_app_number] => 15/772192 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568645 [patent_doc_number] => 20170107289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'INTRACELLULAR DELIVERY COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/298813 [patent_app_country] => US [patent_app_date] => 2016-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 14063 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15298813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421677 [patent_doc_number] => 20170029821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'Methods for eliminating or reducing the expression of genes in filamentous fungal strains by transitive RNA interference' [patent_app_type] => utility [patent_app_number] => 15/296489 [patent_app_country] => US [patent_app_date] => 2016-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21958 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15296489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13457957 [patent_doc_number] => 20180280521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => COMPOUNDS AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/766193 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16277059 [patent_doc_number] => 10760076 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion [patent_app_type] => utility [patent_app_number] => 15/765864 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10832 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393986 [patent_doc_number] => 20170014521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS FOR HIGH-CAPACITY TARGETED DELIVERY' [patent_app_type] => utility [patent_app_number] => 15/285916 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11164 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15285916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410373 [patent_doc_number] => 20180256729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 15/761786 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -371 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649509 [patent_doc_number] => 20170145411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'TREATMENT OF NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NRF2' [patent_app_type] => utility [patent_app_number] => 15/270752 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 27310 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15270752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444067 [patent_doc_number] => 20180273576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS [patent_app_type] => utility [patent_app_number] => 15/761957 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12546945 [patent_doc_number] => 10011856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-03 [patent_title] => Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase [patent_app_type] => utility [patent_app_number] => 15/268424 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 19377 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15268424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675715 [patent_doc_number] => 20160376591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => iRNA AGENTS WITH BIOCLEAVABLE TETHERS [patent_app_type] => utility [patent_app_number] => 15/260803 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15260803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163703 [patent_doc_number] => 10487333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Combination comprising immunostimulatory oligonucleotides [patent_app_type] => utility [patent_app_number] => 15/756798 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 22 [patent_no_of_words] => 8129 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15756798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786250 [patent_doc_number] => 20180153919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 15/258042 [patent_app_country] => US [patent_app_date] => 2016-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 192774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336938 [patent_doc_number] => 20160362694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/247011 [patent_app_country] => US [patent_app_date] => 2016-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 29199 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514652 [patent_doc_number] => 20170081725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'MICRORNA PROFILING FOR DIAGNOSIS OF DYSPLASTIC NEVI AND MELANOMA' [patent_app_type] => utility [patent_app_number] => 15/240207 [patent_app_country] => US [patent_app_date] => 2016-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 28985 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15240207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12470319 [patent_doc_number] => 09988689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-05 [patent_title] => Microrna profiling for diagnosis of dysplastic nevi and melanoma [patent_app_type] => utility [patent_app_number] => 15/229568 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20588 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15229568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13000415 [patent_doc_number] => 10023868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => MiRNA for treating diseases and conditions associated with neo-angiogenesis [patent_app_type] => utility [patent_app_number] => 15/227832 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 24 [patent_no_of_words] => 42109 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457377 [patent_doc_number] => 20170051283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'RNA INTERFERENCE FOR THE TREATMENT OF GAIN-OF-FUNCTION DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/226476 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 36458 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15226476 [rel_patent_id] =>[rel_patent_doc_number] =>)